Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States.

IF 1.7 4区医学 Q3 HEALTH POLICY & SERVICES

Cost Effectiveness and Resource Allocation Pub Date : 2025-06-04 DOI:10.1186/s12962-025-00622-y

Douglas Dietrich, Nancy Reau, Aijaz Ahmed, Rob Blissett, Adam Igloi-Nagy, Alon Yehoshua

{"title":"Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States.","authors":"Douglas Dietrich, Nancy Reau, Aijaz Ahmed, Rob Blissett, Adam Igloi-Nagy, Alon Yehoshua","doi":"10.1186/s12962-025-00622-y","DOIUrl":null,"url":null,"abstract":"<p><p>The hepatitis C virus (HCV) testing and treatment pathway in the United States (US) includes a range of tests and appointments causing delays and loss to follow-up. We assessed the cost-effectiveness of simplifying the pathway using an economic model to estimate health outcomes, cost differences and incremental cost per quality-adjusted life year (QALY) and life year (LY) of the new paradigm compared to the other scenarios. The analysis compared three scenarios, one based on treatment guidelines, one based on real-world practice and a hypothetical scenario with a simplified pathway (\"new paradigm\"); these differed in testing and treatment process steps and times. The new paradigm resulted in cost reductions between $19,751 and $16,448, and excess QALYs between 0.42 and 0.70, suggesting that simplifying the US HCV patient pathway may be cost-effective and allows a quicker path to successful treatment and reduce the number of patients lost to follow-up.</p>","PeriodicalId":47054,"journal":{"name":"Cost Effectiveness and Resource Allocation","volume":"23 1","pages":"25"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135392/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cost Effectiveness and Resource Allocation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12962-025-00622-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

The hepatitis C virus (HCV) testing and treatment pathway in the United States (US) includes a range of tests and appointments causing delays and loss to follow-up. We assessed the cost-effectiveness of simplifying the pathway using an economic model to estimate health outcomes, cost differences and incremental cost per quality-adjusted life year (QALY) and life year (LY) of the new paradigm compared to the other scenarios. The analysis compared three scenarios, one based on treatment guidelines, one based on real-world practice and a hypothetical scenario with a simplified pathway ("new paradigm"); these differed in testing and treatment process steps and times. The new paradigm resulted in cost reductions between $19,751 and $16,448, and excess QALYs between 0.42 and 0.70, suggesting that simplifying the US HCV patient pathway may be cost-effective and allows a quicker path to successful treatment and reduce the number of patients lost to follow-up.

查看原文本刊更多论文

在美国简化丙型肝炎病毒检测、监测和治疗新模式的成本效益分析。

在美国，丙型肝炎病毒（HCV）检测和治疗途径包括一系列检测和预约，导致延误和失去随访。我们使用经济模型来评估简化途径的成本效益，以估计与其他方案相比，新范式的健康结果、成本差异和每个质量调整生命年（QALY）和生命年（LY）的增量成本。该分析比较了三种情景，一种基于治疗指南，一种基于现实世界的实践，以及一种具有简化途径的假设情景（“新范式”）；它们在测试和处理过程步骤和时间上有所不同。新模式导致成本降低19,751美元至16,448美元，超额qaly在0.42至0.70之间，这表明简化美国HCV患者途径可能具有成本效益，并且可以更快地获得成功治疗并减少患者失去随访的数量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cost Effectiveness and Resource Allocation HEALTH POLICY & SERVICES-

CiteScore

3.40

自引率

4.30%

发文量

审稿时长

34 weeks

期刊介绍： Cost Effectiveness and Resource Allocation is an Open Access, peer-reviewed, online journal that considers manuscripts on all aspects of cost-effectiveness analysis, including conceptual or methodological work, economic evaluations, and policy analysis related to resource allocation at a national or international level. Cost Effectiveness and Resource Allocation is aimed at health economists, health services researchers, and policy-makers with an interest in enhancing the flow and transfer of knowledge relating to efficiency in the health sector. Manuscripts are encouraged from researchers based in low- and middle-income countries, with a view to increasing the international economic evidence base for health.